Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome

ClinicalTrials.gov ID: NCT00879606

Public ClinicalTrials.gov record NCT00879606. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy and Safety Evaluation of ALT-836 in Patients With Sepsis and Acute Lung Injury/Acute Respiratory Distress Syndrome

Study identification

NCT ID
NCT00879606
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Altor BioScience
Industry
Enrollment
150 participants

Conditions and interventions

Interventions

  • ALT-836 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2009
Primary completion
Sep 30, 2012
Completion
Dec 31, 2012
Last update posted
Apr 9, 2015

2009 – 2013

United States locations

U.S. sites
20
U.S. states
10
U.S. cities
18
Facility City State ZIP Site status
Los Angeles County and USC Medical Center Los Angeles California 90033
UC Davis Medical Center Sacramento California 95817
Stanford University Stanford California 94305
Yale University New Haven Connecticut 06520
Northwestern University Chicago Illinois 60611
West Suburban Hospital Medical Center Oak Park Illinois 60302
Illinois Lung and Critical Care Institute Peoria Illinois 61606
University of Iowa Iowa City Iowa 52246
Kentucky Lung Clinic Hazard Kentucky 41701
University of Louisville-Division of Pulmonary and Critical Care Louisville Kentucky 40202
Baystate Medical Center Springfield Massachusetts 01199
Saint Luke's Hospital Kansas City Missouri 64111
Saint Louis University St Louis Missouri 63110
Mercy Hospital St. Louis St Louis Missouri 63141
Mount Sinai Medical Center New York New York 10029
Memorial Sloan-Kettering Cancer Center New York New York 10065
Carolinas Medical Center Charlotte North Carolina 28203
Piedmont Respiratory Research Foundation Greensboro North Carolina 27310
Wake Forest University Winston-Salem North Carolina 27157
University of Oklahoma Oklahoma City Oklahoma 73104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00879606, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 9, 2015 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00879606 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →